

# Improving quality of life in patients with intellectual disability and epilepsy through comprehensive inpatient treatment



David Steinbart<sup>1,2</sup> // Anja Grimmer<sup>1</sup> // Rebekka Geelhaar<sup>1</sup> // Martin Holtkamp<sup>1,2</sup>

- <sup>1</sup> Epilepsy-Center Berlin-Brandenburg, Institute for Diagnostics of Epilepsy, Berlin, Germany
- <sup>2</sup> Charité Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany

# Background

- >> Epilepsies in persons with intellectual disability (ID)
- > Prevalence depends on degree of ID: ~10% in people with mild ID up to >50% in persons with profound ID¹
- > Intractable epilepsies in 2/3 of patients<sup>2</sup>
- >> High rate of seizure-related complications3
- > Affects 1/3 of patients over 5 years
- > Status epilepticus, aspiration pneumonia, high SUDEP risk4
- >> Impaired quality of life (QoL)<sup>5</sup>
- > Impact of seizures, complications, adverse events of antiseizure medication (ASM), social isolation, burden of caretaking

# Research questions

- >> Evaluation of effects of comprehensive inpatient treatment on seizure frequency and severity,

  ASM adverse events and QoL
- >> Predictors for improvement of QoL

# Study cohort




Figure 1: Patient cohort.

n: number of patients; QoL: quality of life.

### Methods

- >> Standardized questionnaire completed by care givers
- >> 1 week before admission + 8 weeks after hospital discharge
- >> Descriptive statistics, multiple regression analysis

### Results




Figure 2: Effect of comprehensive treatment on seizure situation and global QoL.

Favorable seizure situation was defined by ≤ 1 seizure/month and no seizure-related injuries in last 2 months. QoL was assessed by care givers on 11-point global rating scale (0 = worst to 10 = best).

Table 1: Predictors for improvement of QoL

Variable	B (95% CI)
ASM number: reduction by 1 ASM	1.4 (0.3 - 2.5)
ASM dose: reduction by 1 DDD	0.6 (-0.4 - 1.5)
3rd generation ASM (portion of DDD +100%)	1.1 (-2.5 - 4.7)
Male sex	-0.1 (-1.5 - 1.4)
Duration of epilepsy (in years)	0.0 (-0.1 - 0.1)
Degree of intellectual disability	0.1 (-0.1 - 0.9)
DDD: defined daily dose	

## Conclusions

>> Effects of comprehensive inpatient treatment: improvement of seizure situation and QoL

>> Reduction of ASM can foster QoL improvement

### References & Contact

References can be found here:



Digital poster copy can be found here:



Get in touch: david.steinbart@charite.de

